"We are pleased to have the opportunity to represent Lotus," said Dave Gentry, President and CEO of RedChip Companies, Inc. "China is one of the world's largest and fastest-growing pharmaceutical markets, with annual sales expected to reach $24 billion in 2010. Continued economic development within China, as well as Chinese government policies aimed at expanding citizens' access to healthcare, is anticipated to drive future growth in this sector. With its strong R&D capabilities, innovative product development pipeline and well-established national distribution network, Lotus is poised to become a market leader. We look forward to introducing them to our investor network as we implement a comprehensive investor relations program that includes research, radio programming, road shows and investor conferences."
About Lotus Pharmaceuticals, Inc.
Lotus Pharmaceuticals, Inc. is a growing developer and producer of drugs
and a licensed national seller of pharmaceutical items in the People's
Republic of China (PRC). Lotus operates its business through its two
controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi
Pharmaceutical, Ltd. Lotus' current drug development is focused on the
treatment of cerebro-cardiovascular diseases, asthma and diabetes. Liang Fang
sells drugs directly and indirectly through its national sales channels to
hospitals, clinics and drugs stores in 30 provinces of the
|SOURCE Lotus Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved